In tumour organoids derived from mice with combined Brca1 and Tp53 loss-of-function mutations (WB1P)41 we found that CB-5083 further sensitized tumour organoids to talazoparib (Fig. 6g and Extended Data Fig. 9h). This evidence concerns the gene BRCA1 and neoplasm.